Search for drugs:
Typing the drug name to query
APIXABAN
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- Apixaban has no effect on the QTc interval in humans at doses up to 50 mg.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
17
24075
Other ADRs
149681
38231906
Odds Ratio = 0.181
Drug Property Information
ATC Code(s):
- B01AF02 - apixaban
- B01AF0 -
- B01AF -
- B01A - ANTITHROMBOTIC AGENTS
- B01 - ANTITHROMBOTIC AGENTS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:apixaban
Active Ingredient UNII:3Z9Y7UWC1J
Drugbank ID:DB06605
PubChem Compound:10182969
CTD ID:C522181
PharmGKB:PA166163740
CAS Number:503612-47-3
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 10.0 mg/day B01AF02
Chemical Structure: 
SMILE Code:
COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.